What do CJC-1295, Ipamorelin, and IGF-1 LR3 actually do? A science-backed, source-cited breakdown of the research, risks, and legal status.
A Quick Peptide Primer
CJC-1295: A Long-Acting GHRH Analog
Ipamorelin: The "Selective" Secretagogue
Why They're Stacked Together
IGF-1 LR3: A Stronger, Longer-Lasting Mimic
The Legal and Regulatory Reality
Where This Leaves You
Key Takeaways
Frequently Asked Questions
Sources
Want Real Results Without the Gray Market?
What does CJC-1295 actually do? CJC-1295 is a long-acting analog of growth hormone-releasing hormone (GHRH). In a 2006 randomized, placebo-controlled trial in healthy adults, a single injection raised growth hormone 2- to 10-fold for six days or more and increased IGF-1 1.5- to 3-fold for 9–11 days. The study confirmed the pharmacology, but it did not measure muscle growth, fat loss, or athletic performance.
How is Ipamorelin different from older growth hormone-releasing peptides? Ipamorelin stimulates the ghrelin receptor to trigger a growth hormone pulse. A 1998 study found it raised GH with potency comparable to GHRP-6, but without significantly raising ACTH or cortisol — the stress hormones commonly elevated by older secretagogues like GHRP-6 and GHRP-2.
Is the CJC-1295 + Ipamorelin stack proven for muscle or fat loss? No. The individual compounds have published human data showing they elevate GH and IGF-1, but there is no peer-reviewed human trial testing the specific combination for outcomes like lean mass, strength, fat loss, sleep quality, or recovery in healthy adults. Most body-composition claims for the stack are extrapolated or come from marketing, not controlled research.
What is IGF-1 LR3 and why is it considered higher risk? IGF-1 LR3 is a modified, longer-acting analog of IGF-1 engineered to bypass binding proteins. It activates anabolic signaling pathways, but it also has strong insulin-like activity. Reported risks include acute hypoglycemia severe enough to cause seizures, cardiac tissue enlargement, connective tissue overgrowth, and theoretical concerns about promoting growth of existing malignant or pre-malignant cells. Long-term human safety data are lacking.
Can competitive athletes use these peptides? No. Growth hormone-releasing peptides and IGF-1 are prohibited at all times — in and out of competition — on the World Anti-Doping Agency Prohibited List under peptide hormones and growth factors. USADA also warns that unregulated products labeled as IGF-1 may not contain IGF-1 at all, creating additional purity and dosing risks.